SK bioscience

At SK bioscience, we work everyday to promote human health from prevetion to cure. We have successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., and a universal vaccine to prevent ‘Sarbecovirus.’ We have also developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. We are expanding our R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In addition, SK bioscience signed a CMO contract to manufacture AstraZeneca's COVID-19 vaccine from drug substance to drug product at L-House, SK bioscience’s vaccine manufacturing plant, and contributed to the early prevention of COVID-19, recognized as a global hub for vaccine manufacturing. Based on innovative technology, all pf our colleagues are trying to achieve the company’s mission, ‘We promote human health, from prevention to cure.’ To meet social expectations, SK bioscience will build trust as a global innovative partner of vaccine and biotech so that all stakeholders, including employees, customers, shareholders, and local communities, could be proud and happy.